Please use this identifier to cite or link to this item:
http://nopr.niscpr.res.in/handle/123456789/57837Full metadata record
| DC Field | Value | Language |
|---|---|---|
| dc.contributor.author | Gullapelli, Kumaraswamy | - |
| dc.contributor.author | Maroju, Ravichandar | - |
| dc.contributor.author | Merugu, Ramchander | - |
| dc.date.accessioned | 2021-08-05T06:01:37Z | - |
| dc.date.available | 2021-08-05T06:01:37Z | - |
| dc.date.issued | 2021-05 | - |
| dc.identifier.issn | 0975-0991 (Online); 0971-457X (Print) | - |
| dc.identifier.uri | http://nopr.niscair.res.in/handle/123456789/57837 | - |
| dc.description | 343-350 | en_US |
| dc.description.abstract | The present study is the synthesis of new heterocyclic moieties like pyrazole, isoxazole and thiazole containing benzimidazole nucleus. The title compounds were synthesized from 4-(1H-benzo[d]imidazol-2-yl) oxazol-2-amine. The newly synthesised compounds were screened for their in vitro anti-inflammatory activity and demonstrated excellent to moderate activity and molecular docking study reports are supporting anti-inflammatory activity showed high inhibition constant and binding energy. The structures of synthesised compounds were characterized by IR, 1HNMR, Mass spectroscopic methods. | en_US |
| dc.publisher | NIScPR-CSIR, India | en_US |
| dc.source | IJCT Vol.28(3) [May 2021] | en_US |
| dc.subject | Benzimidazole | en_US |
| dc.subject | Docking study | en_US |
| dc.subject | Isoxazole | en_US |
| dc.subject | Pyrazole | en_US |
| dc.subject | Synthesis | en_US |
| dc.title | An efficient synthesis, invitro and insilco evaluation of new pyrazole and isoxazole derivatives as anti-inflammatory agents | en_US |
| dcterms.publisher | NISCAIR-CSIR, India | en_US |
| dcterms.source | IJCT Vol.28(3) [May 2021] | en_US |
| Appears in Collections: | IJCT Vol.28(3) [May 2021] | |
Files in This Item:
| File | Description | Size | Format | |
|---|---|---|---|---|
| IJCT 28(3) 343-350.pdf | 397.2 kB | Adobe PDF | View/Open |
Items in NOPR are protected by copyright, with all rights reserved, unless otherwise indicated.